Transient neonatal myasthenia gravis

Transient neonatal myasthenia gravis is a rare condition that affects about 10% to 15% of babies born to mothers with myasthenia gravis (MG).

Much like the adult form of the disease, this condition occurs when the immune system mistakenly attacks the communication points between nerves and muscles, a process driven by self-reactive antibodies. However, unlike adult MG, these infants do not produce their own disease-causing antibodies. Instead, they receive them from their mother during fetal development.

Transient neonatal MG is temporary. It typically clears up without major complications in the weeks or months following birth as the baby’s own immune system matures. It is one of several conditions that can cause MG-like symptoms in children, alongside juvenile MG and congenital myasthenic syndromes (CMS).

Causes

In MG, the body mistakenly produces self-reactive antibodies that attack the proteins essential for nerve-muscle communication. When these signals are interrupted, it causes characteristic symptoms of muscle weakness and fatigue.

Maternal antibody transfer in newborns occurs during pregnancy when a mother’s antibodies travel through the placenta to the developing fetus. This process, known as transplacental transmission, is a normal part of development. It usually serves a vital purpose by protecting newborns from infections early in life while their own immune systems are still maturing.

However, if a mother has MG, her self-targeting antibodies can also cross the placenta along with the protective ones. Once these antibodies enter the baby’s bloodstream, they can begin to interfere with the infant’s nerve-muscle signals, leading to temporary weakness after birth.

Through this natural transfer process, a mother with MG can pass disease-causing antibodies to the fetus, primarily during the second and third trimesters. The antibodies most often linked to transient neonatal MG include those that target:

• acetylcholine receptors (AChR)
• muscle-specific kinase (MuSK)

Anti-AChR antibodies are more common than anti-MuSK antibodies in adults, and the same is true for babies. In rare cases, mothers with seronegative MG — meaning they have no identifiable antibodies in their blood — may also give birth to infants with the condition.

While antibodies against the protein low-density lipoprotein receptor-related protein 4 (LRP4) are known to cause MG, there are no reported cases of this causing the neonatal form yet. This could be because LRP4 was discovered more recently, and testing is not as widely available.

Interestingly, most babies born to mothers with MG will test positive for these antibodies at birth, but only 10% to 15% will actually show symptoms. Scientists still do not fully understand why this is the case. The baby’s condition does not seem to depend on how severe the mother’s symptoms are; in fact, a baby can develop the condition even if the mother has few or no active symptoms.

A mother who has already given birth to one child with transient neonatal MG has a higher risk of her future children having it as well. Conversely, if a mother has had a thymectomy — a surgery to remove the thymus gland — it may decrease the risk for her baby.

Symptoms

Symptoms of transient neonatal MG usually appear within the first 24 hours of life for about 80% of affected infants. However, it can occasionally take up to four days for the first signs to emerge. In some cases, evidence of the condition can even be detected before birth through prenatal monitoring.

Common signs

The most common signs of transient neonatal MG usually appear shortly after birth. These symptoms are primarily caused by muscle weakness that affects the face, head, and neck.

Common transient neonatal MG symptoms include:

• weak cry in newborns: Babies may struggle to make a loud or sustained sound when crying.
• feeding difficulties: This includes weak sucking or swallowing, and the baby may become easily exhausted during feedings.
• breathing difficulties: Weakness in the chest muscles can make it hard for the infant to breathe deeply.
• floppy baby syndrome: This is a state of low muscle tone, also known as hypotonia.
• facial weakness: Signs include drooping eyelids, an open mouth, and a lack of varied facial expressions.

Feeding and sucking difficulties are particularly concerning because they can lead to food regurgitation, dehydration, and poor weight gain. General hypotonia might be noticed when a baby has poor head control or rests their legs in an unusual “frog position.”

Prenatal indicators

Doctors may notice signs of abnormal development before birth that suggest a baby is affected by transient neonatal MG. These signs are usually only visible on an ultrasound in more severe cases and include:

• reduced fetal movement: The baby may not kick or move as frequently as expected.
• skeletal abnormalities: This can include conditions like clubfoot, where the foot is twisted out of shape or position.
• excessive amniotic fluid: This occurs when fetal muscles are too weak to support normal swallowing. Without the fetus swallowing fluid as part of a healthy cycle, the fluid levels in the womb can become too high, causing unexpected swelling of the mother’s belly.

Changes in fetal movement and the presence of clubfoot can be signs of joint contractures. This happens when the connective tissue around a joint stiffens, making movement very difficult. In some severe instances, a fetus may develop multiple contractures across different parts of the body, a condition known as arthrogryposis multiplex congenita.

Because these symptoms are driven by the mother’s antibodies, doctors who are aware of a mother’s MG diagnosis will often monitor these factors closely during pregnancy to prepare for the baby’s needs at birth.

Diagnosis

Identifying symptoms suggesting muscle weakness in infants is often enough to reach a diagnosis if the mother already has a known MG diagnosis. If the mother’s health history is unclear or if there is uncertainty about the baby’s symptoms, doctors use specialized tests to confirm the condition.

These diagnostic tools include:

• antibody blood tests: Identifying proteins that cause MG helps confirm that self-targeting antibodies have traveled from the mother to the baby.
• the neostigmine test in newborns: Using medication to check for strength involves a small dose of neostigmine to temporarily boost muscle function. If the infant has the condition, their muscle weakness usually improves for a short time after the dose.
• repetitive nerve stimulation (RNS): Assessing nerve-muscle communication uses electrical pulses to see how well muscles respond to signals. This test is a standard tool for adults, but is difficult to perform on newborns and is rarely required.

To ensure an accurate diagnosis, doctors must rule out other conditions that can mimic muscle weakness in infants. Several of these issues can be life-threatening and require immediate medical attention.

The diagnostic process involves distinguishing MG from the following:

• Congenital myasthenic syndromes: Identifying genetic communication disorders that affect the neuromuscular junction, much like MG, but are caused by gene mutations rather than antibodies
• Perinatal asphyxia: Assessing oxygen deprivation during birth, which can lead to low muscle tone and neurological challenges in the first days of life
• Congenital muscular dystrophy: Checking for genetic muscle wasting that results in permanent weakness and structural changes in muscle tissue
• Metabolic and blood issues: Evaluating hypoglycemia or hypovolemia to ensure that low blood sugar or decreased blood volume is not the underlying cause of the baby’s fatigue
• Neonatal sepsis: Screening for severe infection responses that can make a newborn appear extremely weak and unresponsive
• Structural heart or lung problems: Testing for heart disease or respiratory distress to rule out conditions where the baby’s heart or lungs are not providing enough oxygen to the muscles

Pinpointing the cause of muscle weakness is vital to ensuring a baby receives the correct medical care. While many of these conditions require long-term management or emergency intervention, transient neonatal MG is unique because it resolves on its own once maternal antibodies are cleared.

Treatment options and supportive care

Most babies with transient neonatal MG recover naturally within a few weeks or months as maternal antibodies gradually leave their system. Infants are usually monitored in the hospital for a few days to ensure they are stable before heading home.

Treatment typically involves minor supportive care, but some cases require more significant medical intervention. Because every baby is different, families should work closely with their healthcare team and newborn specialists. There are currently no definitive neonatologist clinical guidelines for treating transient neonatal MG, so doctors base treatment decisions on each infant’s specific needs.

Mothers with MG should also seek regular guidance from their own specialists during and after pregnancy. Maternal MG management strategies often need to be adjusted because certain medications may not be safe for use during pregnancy or while breastfeeding. Working with a coordinated care team ensures both mother and baby receive the safest and most effective care possible.

Medications

Medications and more intensive medical interventions can help manage symptoms while the baby waits for the maternal antibodies to clear.

Treatment options for infants include:

• acetylcholinesterase inhibitors: Boosting nerve-muscle signaling with medications like Mestinon (pyridostigmine bromide) or neostigmine to improve muscle strength. Many doctors prefer pyridostigmine for neonates because its effects last longer and it typically causes fewer side effects than other options.
• intravenous immunoglobulin (IVIG): Neutralizing harmful antibodies through an infusion that delivers healthy donor antibodies into the baby’s bloodstream. This helps reduce the impact of the mother’s self-targeting antibodies.
• plasmapheresis: Filtering the blood to physically remove disease-causing antibodies from circulation. This is a highly specialized procedure used in more serious cases.

Both plasmapheresis and intravenous immunoglobulin for babies require infusions into a vein. Because these procedures are more complex, they are typically reserved for infants with severe weakness or significant breathing and feeding challenges.

As maternal antibodies naturally decline, the need for these medications also decreases. Most babies can be successfully tapered off treatment within a few weeks as they gain strength and their immune systems begin to function independently.

Respiratory and nutritional support

While most babies recover naturally, supportive care is vital to ensure they remain strong and healthy during the first few weeks of life.

Common supportive measures include:

• nutritional management: Providing small, frequent feedings to help babies who tire easily due to muscle weakness. Smaller meals allow infants to get enough nutrition and hydration without becoming too exhausted to suck or swallow.
• advanced feeding support: Using a feeding tube when a baby is unable to take in enough milk by mouth. This ensures they maintain a healthy weight while their strength gradually returns.
• hydration support: Delivering intravenous fluids to prevent dehydration if an infant is struggling with food regurgitation or poor intake.
• respiratory support for infants: Assisting with breathing through noninvasive techniques like nasal oxygen tubes or continuous airway pressure masks. In more severe cases, doctors may use a breathing tube to ensure the baby receives enough oxygen.

For mothers who wish to breastfeed, the process is usually safe as long as they are not taking specific MG medications that could pass into the breastmilk and affect the baby. Maternal MG management should always be discussed with a specialist to ensure breastfeeding is safe for both mother and child.

As the mother’s antibodies naturally fade, these supportive measures are slowly reduced. Most infants transition to normal feeding and breathing patterns within a month of birth.

Prognosis

The timeline for spontaneous resolution of transient neonatal MG is generally short. While the exact duration varies for every baby, the vast majority experience a full recovery as the mother’s antibodies naturally leave their system.

Key recovery milestones include:

• two-month recovery: Reaching full strength for most babies, as approximately 90% of infants see their symptoms completely disappear within the first eight weeks of life
• four-month resolution: Clearing symptoms in remaining cases for the small percentage of babies who take a little longer to process the maternal antibodies
• no long-term impact: Maintaining a healthy future because there are typically no lasting physical or neurological effects from this temporary condition
• no increased risk: Developing MG later in life is not more likely for these infants, as their own immune system was never the source of the problem

Once the recovery is complete, these children meet their developmental milestones just like any other infant. Because the condition is not genetic or a permanent flaw in the baby’s immune system, families can look forward to a healthy childhood without the need for ongoing MG treatments.